Blood

Vol. 145, Issue 21 Issue 21 2025
18
Articles

Articles in this Issue

A novel way for transglutaminase 2 to mitigate liver damage

Muriel C. Maurer May 22, 2025 pp. 2407-2408 10.1182/blood.2025028561

Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response

Sravya Tumuluru, James K. Godfrey, Alan Cooper et al. May 22, 2025 pp. 2460-2472 10.1182/blood.2024025355

Abstract Most patients with diffuse large B-cell lymphoma (DLBCL) treated with immunotherapies such as bispecific antibodies (BsAbs) or chimeric antigen receptor (CAR) T cells fail t...

Inflammation conjoins differentiation and resistance in AML

Maike Janssen, Carsten Müller-Tidow May 22, 2025 pp. 2405-2407 10.1182/blood.2025028651

Immunotherapy response: is it all in the DLBCL-IQs?

Jessica Okosun May 22, 2025 pp. 2402-2403 10.1182/blood.2025028443

How I approach pharmacological thromboprophylaxis in children

Anthony A. Sochet, Amy Kiskaddon, Neil A. Goldenberg May 22, 2025 pp. 2439-2446 10.1182/blood.2024026327

Abstract The incidence of venous thromboembolism in children continues to rise, with the most recent analysis from the Pediatric Hospital Information Systems database in the United S...

Haploidentical HSCT: more curative options for patients with CGD

Emma C. Morris May 22, 2025 pp. 2408-2409 10.1182/blood.2025028904

Chromatin dynamics in CLL: a matter of balance

Richard Rosenquist May 22, 2025 pp. 2403-2405 10.1182/blood.2024028201

Clonal hematopoiesis landscape in frequent blood donors

Darja Karpova, Hector Huerga Encabo, Elisa Donato et al. May 22, 2025 pp. 2411-2423 10.1182/blood.2024027999

Abstract Donor blood saves lives, yet the potential impact of recurrent large-volume phlebotomy on donor health and hematopoietic stem cells (HSCs) remains largely unexplored. In our...

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia

Basil Allen, Daniel Bottomly, Thomas Köhnke et al. May 22, 2025 pp. 2488-2506 10.1182/blood.2024028239

Abstrat MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patien...

Lymphoid malignancies in patients with Shwachman-Diamond syndrome

Helen D. Reed, Hyunwoo Do, Edie Weller et al. May 22, 2025 pp. 2528-2532 10.1182/blood.2024026507

Abstract This study identified an increased risk of lymphoid malignancy in Shwachman-Diamond syndrome (SDS) with an observed risk 38-fold higher than expected based on population dat...

Integrated cross-linking by TG2 and FXIII generates hepatoprotective fibrin(ogen) deposits in injured liver

Zimu Wei, Nana Kwame Kwabi Boateng, Lauren R. Schmitt et al. May 22, 2025 pp. 2507-2517 10.1182/blood.2024026938

Abstract The transglutaminase coagulation factor XIII (FXIII) is critical for the stability and function of intravascular fibrin clots. Prorepair extravascular fibrin(ogen) deposits...

Advances in RNA editing in hematopoiesis and associated malignancies

Shuangshuang Pu, Tao Cheng, Hui Cheng May 22, 2025 pp. 2424-2438 10.1182/blood.2024027379

Abstract Adenosine-to-inosine (A-to-I) RNA editing is a prevalent RNA modification essential for cell survival. The process is catalyzed by the adenosine deaminase acting on RNA (ADA...

Classic hairy cell leukemia and concomitant smoldering myeloma

Husam Jum’ah, David Viswanatha May 22, 2025 pp. 2533-2533 10.1182/blood.2025028465

Blitzing ALL with blinatumomab

Mark R. Litzow May 22, 2025 pp. 2400-2402 10.1182/blood.2025028576

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

Quentin Riller, Mathias Hauri, Su Han Lum et al. May 22, 2025 pp. 2518-2527 10.1182/blood.2024026915

Abstract Chronic granulomatous disease (CGD) is an inborn error of immunity characterized by defective NAD phosphate oxidase function, leading to impaired microbial killing, recurren...

Of donors and dynamics

Alyssa H. Cull, David G. Kent May 22, 2025 pp. 2399-2400 10.1182/blood.2025028660

Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Renato Bassan, Sabina Chiaretti, Irene Della Starza et al. May 22, 2025 pp. 2447-2459 10.1182/blood.2024027500

Abstract The Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Leucemia Acuta Linfoblastica (LAL) 2317 protocol investigated the frontline chemotherapy-blinatumomab combinat...

Dual biological role and clinical impact of de novo chromatin activation in chronic lymphocytic leukemia

Vicente Chapaprieta, Alba Maiques-Diaz, Ferran Nadeu et al. May 22, 2025 pp. 2473-2487 10.1182/blood.2024025396

Abstract Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern compared with normal B cells. Here, we explored whether t...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page